Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer

Improved vectors and genome-wide libraries for CRISPR screening

Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · see citing works

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · see citing works

A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells

Roux, K. J., Kim, D. I., Raida, M., & Burke, B. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201112098 · Cited by 2,416 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043 · see citing works

RAS Proteins and Their Regulators in Human Disease

Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · see citing works

The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants

Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · see citing works

Ras oncogenes: split personalities

Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · see citing works

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,016 · see citing works

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · see citing works

Endomembrane Trafficking of Ras

Choy, E., Chiu, V. K., Silletti, J., Feoktistov, M., Morimoto, T., Michaelson, D., Ivanov, I. E., & Philips, M. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80607-8 · Cited by 754 · see citing works

Ras history: The saga continues

Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706 · see citing works

KRAS: feeding pancreatic cancer proliferation

Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675 · see citing works

Both p16 Ink4a and the p19 Arf -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse

Bardeesy, N. M., Aguirre, A. J., Chu, G. C., Cheng, K., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C. W., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 575 · see citing works

The Biology and Enzymology of ProteinN-Myristoylation

Farazi, T. A., Waksman, G., & Gordon, J. I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100042200 · Cited by 556 · see citing works

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.

Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · see citing works

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · see citing works

A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.

Hancock, J. F., Cadwallader, K. A., Paterson, H., & Marshall, C. J. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04979.x · Cited by 482 · see citing works

Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase

Yan, J., Roy, S., Apolloni, A., Lane, A., & Hancock, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24052 · Cited by 477 · see citing works

Ras effectors

Marshall, C. J. (1996) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(96)80066-4 · Cited by 463 · see citing works

Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo

Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368 · see citing works

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes

Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26802 · Cited by 361 · see citing works

The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins

Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325 · see citing works

Promiscuous protein biotinylation by Escherichia coli biotin protein ligase

Choi‐Rhee, E., Schulman, H., & Cronan, J. E. (2004) · Protein Science · doi:10.1110/ps.04911804 · Cited by 297 · see citing works

Rsk1 mediates a MEK–MAP kinase cell survival signal

Shimamura, A., Ballif, B. A., Richards, S. A., & Blenis, J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00310-9 · Cited by 296 · see citing works

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265 · see citing works

RSK Is a Principal Effector of the RAS-ERK Pathway for Eliciting a Coordinate Promotile/Invasive Gene Program and Phenotype in Epithelial Cells

Doehn, U., Hauge, C., Frank, S. R., Jensen, C. J., Duda, K., Nielsen, J. V., Cohen, M. S., Johansen, J. V., Winther, B. R., Lund, L. R., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.002 · Cited by 228 · see citing works

PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network

Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0031 · Cited by 223 · see citing works

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 212 · see citing works

RSK and MSK in MAP kinase signalling

Hauge, C., & Frödin, M. (2006) · Journal of Cell Science · doi:10.1242/jcs.02950 · Cited by 204 · see citing works

Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells

Baghirova, S., Hughes, B. G., Hendzel, M. J., & Schulz, R. (2015) · MethodsX · doi:10.1016/j.mex.2015.11.001 · Cited by 203 · see citing works

Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer

Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., Yao, M. A., Alagesan, P., Zaatari, M. N., Park, Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1409 · Cited by 198 · see citing works

Phosphorylation of p90 Ribosomal S6 Kinase (RSK) Regulates Extracellular Signal-Regulated Kinase Docking and RSK Activity

Roux, P. P., Richards, S. A., & Blenis, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.14.4796-4804.2003 · Cited by 196 · see citing works

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183 · see citing works

Metastatic pancreatic cancer is dependent on oncogenic Kras in mice

Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178 · see citing works

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis

Jeng, H., Taylor, L. J., & Bar‐Sagi, D. (2012) · Nature Communications · doi:10.1038/ncomms2173 · Cited by 176 · see citing works

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176 · see citing works

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest

Morton, J. P., Jamieson, N. B., Karim, S. A., Athineos, D., Ridgway, R. A., Nixon, C., McKay, C. J., Carter, R., Brunton, V. G., Frame, M. C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.055 · Cited by 169 · see citing works

Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities

Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 164 · see citing works

A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1Preprint

Stowe, I. B., Mercado, E. L., Stowe, T. R., Bell, E. L., Osés-Prieto, J. A., Hernández, H., Burlingame, A. L., & McCormick, F. P. (2012) · Genes & Development · doi:10.1101/gad.190876.112 · Cited by 158 · see citing works

Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis

McGillicuddy, L. T., Longo, J. F., Hollstein, P. E., Kubek, S., Beroukhim, R., Raedt, T. D., Johnson, B. W., Williams, S. M. G., Nghiemphu, P. L., Liau, L. M., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.009 · Cited by 155 · see citing works

The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2

Kovalski, J. R., Bhaduri, A., Zehnder, A. M., Neela, P. H., Che, Y., Wozniak, G. G., & Khavari, P. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.001 · Cited by 154 · see citing works

BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors

Dingar, D., Kalkat, M., Chan, P.-K., Srikumar, T., Bailey, S. D., Tu, W. B., Coyaud, E., Ponzielli, R., Kolyar, M., Jurisica, I., et al. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2014.09.029 · Cited by 131 · see citing works

RSK Isoforms in Cancer Cell Invasion and Metastasis

Sulzmaier, F. J., & Ramos, J. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1087 · Cited by 126 · see citing works

Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling

Terrell, E. M., Durrant, D., Ritt, D. A., Sealover, N. E., Sheffels, E., Spencer-Smith, R., Esposito, D., Zhou, Y., Hancock, J. F., Kortum, R. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.004 · Cited by 115 · see citing works

Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer

Liu, M., Sjogren, A.-K. M., Karlsson, C., Ibrahim, M. X., Andersson, K., Olofsson, F. J., Wahlstrom, A. M., Dalin, M. G., Yu, H., Chen, Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908396107 · Cited by 113 · see citing works

Defining the role of the RSK isoforms in cancer

Houlès, T., & Roux, P. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.016 · Cited by 113 · see citing works

Characterization of Regulatory Events Associated with Membrane Targeting of p90 Ribosomal S6 Kinase 1

Richards, S. A., Dreisbach, V. C., Murphy, L. O., & Blenis, J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7470-7480.2001 · Cited by 104 · see citing works

Biotin ligase tagging identifies proteins proximal to E-cadherin, including lipoma preferred partner, a regulator of epithelial cell-cell and cell-substrate adhesion

Itallie, C. M. V., Tietgens, A. J., Aponte, A. M., Fredriksson, K., Fanning, A. S., Guček, M., & Anderson, J. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.140475 · Cited by 96 · see citing works

Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion

Quinlan, M. P., Quatela, S. E., Philips, M. R., & Settleman, J. E. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01661-07 · Cited by 95 · see citing works

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

Spadi, R. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.27 · Cited by 90 · see citing works

RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation

Saha, M., Carriere, A., Cheerathodi, M., Zhang, X., Lavoie, G., Rush, A. J., Roux, P. P., & Ballif, B. A. (2012) · Biochemical Journal · doi:10.1042/bj20120938 · Cited by 88 · see citing works

Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability

Adhikari, H., & Counter, C. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05692-6 · Cited by 88 · see citing works

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 84 · see citing works

Developmentally-regulated expression of murine K-ras isoforms

Pells, S., Divjak, M., Romanowski, P., Impey, H., Hawkins, N. J., Clarke, A. R., Hooper, M. L., & Williamson, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201354 · Cited by 83 · see citing works

Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death

Froeling, F. E. M., Swamynathan, M. M., Deschênes, A., Chio, I. I. C., Brosnan, E., Yao, M. A., Alagesan, P., Lucito, M. S., Li, J., Chang, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0302 · Cited by 81 · see citing works

K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer.

Plowman, S. J., Berry, R. L., Bader, S. A., Luo, F., Arends, M. J., Harrison, D. J., Hooper, M. L., & Patek, C. E. (2006) · PubMed · Cited by 70 · see citing works

RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma

Houlès, T., Gravel, S., Lavoie, G., Shin, S., Savall, M., Méant, A., Grondin, B., Gaboury, L. A., Yoon, S.-O., St‐Pierre, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2215 · Cited by 62 · see citing works

A proximity-dependent biotinylation map of a human cell: an interactive web resourcePreprint

Go, C. D., Knight, J. D. R., Rajasekharan, A., Rathod, B., Hesketh, G. G., Abe, K. T., Youn, J.-Y., Samavarchi-Tehrani, P., Zhang, H., Zhu, L. Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/796391 · Cited by 57 · see citing works

Marked by association: techniques for proximity-dependent labeling of proteins in eukaryotic cells

Roux, K. J. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1287-3 · Cited by 43 · see citing works

Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis

Kong, G., Chang, Y.-I., Damnernsawad, A., You, X., Du, J., Ranheim, E. A., Lee, W. L., Ryu, M.-J., Zhou, Y., Xing, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.40 · Cited by 43 · see citing works

Proteomic analysis of HIV-1 Gag interacting partners using proximity-dependent biotinylation

Sage, V. L., Cinti, A., Valiente‐Echeverría, F., & Mouland, A. J. (2015) · Virology Journal · doi:10.1186/s12985-015-0365-6 · Cited by 42 · see citing works

Challenges in Ras therapeutics in pancreatic cancer

Choi, M., Bien, H., Mofunanya, A., & Powers, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.015 · Cited by 39 · see citing works

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice

Staffas, A., Karlsson, C., Persson, M., Palmqvist, L., & Bergö, M. O. (2014) · Leukemia · doi:10.1038/leu.2014.315 · Cited by 38 · see citing works

Feedback activation of neurofibromin terminates growth factor-induced Ras activation

Hennig, A., Markwart, R., Wolff, K., Schubert, K., Cui, Y., Prior, I. A., Esparza-Franco, M. A., Ladds, G., & Rubio, I. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0128-z · Cited by 35 · see citing works

SH3P2 is a negative regulator of cell motility whose function is inhibited by ribosomal S6 kinase-mediated phosphorylation

Tanimura, S., Hashizume, J., 黒崎由希子, Sei, K., Gotoh, A., Ohtake, R., Kawano, M., Watanabe, K., & Kohno, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2011.01503.x · Cited by 28 · see citing works

Ras hitchhikes on PDE6δ

Philips, M. R. (2012) · Nature Cell Biology · doi:10.1038/ncb2429 · Cited by 26 · see citing works

Gemcitabine. New first-line therapy for pancreatic cancer.

Rs, K. (1997) · PubMed · Cited by 26 · see citing works

Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion

Méant, A., Gao, B., Lavoie, G., Nourreddine, S., Jung, F., Aubert, L., Tcherkezian, J., Gingras, A., & Roux, P. P. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001811 · Cited by 20 · see citing works

SPRED proteins provide a NF-ty link to Ras suppressionPreprint

McClatchey, A. I., & Cichowski, K. M. (2012) · Genes & Development · doi:10.1101/gad.197434.112 · Cited by 15 · see citing works

Analysis of K-Ras Interactions by Biotin Ligase Tagging

Ritchie, C., Mack, A. R., Harper, L., Alfadhli, A., Stork, P. A., Nan, X., & Barklis, E. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20034 · Cited by 14 · see citing works

Fixing a Hole Where the Ras Gets In

Iwig, J. S., & Kuriyan, J. (2013) · Cell · doi:10.1016/j.cell.2013.05.029 · Cited by 5 · see citing works

Alternative splicing and related RNA binding proteins in human health and disease

Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 342 · see citing works

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231 · see citing works

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Ryan, M. B., Coker, O., Sorokin, A., Fella, K., Barnes, H., Wong, E., Kanikarla, P., Gao, F., Zhang, Y., Zhou, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110993 · Cited by 177 · see citing works

Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer

Wan, L., Lin, K., Rahman, M. A., Ishigami, Y., Wang, Z., Jensen, M. A., Wilkinson, J. E., Park, Y., Tuveson, D. A., & Krainer, A. R. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1013 · Cited by 73 · see citing works

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

Baghini, S. S., Gardanova, Z. R., Abadi, S. A. H., Zaman, B. A., İlhan, A., Shomali, N., Adili, A., Moghaddar, R., & Yaseri, A. F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00336-6 · Cited by 46 · see citing works

Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg

Rosen, J. C., Sacher, A. G., & Tsao, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160141 · Cited by 22 · see citing works

Discovery of potential RSK1 inhibitors for cancer therapy using virtual screening, molecular docking, molecular dynamics simulation, and MM/GBSA calculations

Kalın, S., & Önder, F. C. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2291830 · Cited by 24 · see citing works

Phosphoserine Aminotransferase 1: A Metabolic Enzyme Target of Cancers

Chen, Y., Yang, X. F., & Li, C. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220829105300 · Cited by 20 · see citing works

D154Q Mutation does not Alter KRAS Dimerization

Grozavu, I., Stuart, S. E., Lyakisheva, A., Yao, Z., Pathmanathan, S., Ohh, M., & Štagljar, I. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167392 · Cited by 16 · see citing works

ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses

Lannigan, D. A. (2022) · Endocrinology · doi:10.1210/endocr/bqac106 · Cited by 16 · see citing works

ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells

Khandakar, G. I., Satoh, R., Takasaki, T., Fujitani, K., Tanabe, G., Sakai, K., Nishio, K., & Sugiura, R. (2022) · Cells · doi:10.3390/cells11040702 · Cited by 15 · see citing works

The ribosomal S6 kinase 2 (RSK2)–SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling

Lopez, J., Bonsor, D. A., Sale, M. J., Urisman, A., Mehalko, J. L., Cabanski-Dunning, M., Castel, P., Simanshu, D. K., & McCormick, F. P. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104789 · Cited by 11 · see citing works

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex

Damianou, A., Liang, Z., Lassen, F. H., Vendrell, I., Vere, G., Hester, S., Charles, P. D., Pinto-Fernández, A., Santos, A., Fischer, R., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302245 · Cited by 9 · see citing works

SPRED2 Is a Novel Regulator of Autophagy in Hepatocellular Carcinoma Cells and Normal Hepatocytes

Wang, T., Gao, T., Fujisawa, M., Ohara, T., Sakaguchi, M., Yoshimura, T., & Matsukawa, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116269 · Cited by 9 · see citing works

Multifunctional Proximity Labeling Strategy for Lipid Raft-Specific Sialic Acid Tracking and Engineering

Guo, Y., Wang, P., Jiang, L., Deng, C., Zheng, L., Song, C., & Jiao, J. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00236 · Cited by 6 · see citing works

The RAS Signaling Network and Cancer

Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4 · see citing works

LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc

Cheng, C., Liu, Z., Liu, D., Chen, H., Wang, Y., & Sun, B. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad076 · Cited by 3 · see citing works

Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS MutationsPreprint

Damianou, A., Liang, Z., Lassen, F. H., Vere, G., Hester, S., Charles, P. D., Pinto-Fernández, A., Santos-Delgado, A., Fischer, R., & Kessler, B. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.23.469679 · Cited by 3 · see citing works

Unlocking the Genetic Secrets of Pancreatic Cancer: KRAS Allelic Imbalances in Tumor Evolution

Liaki, V., Rosas-Pérez, B., & Guerra, C. E. (2025) · Cancers · doi:10.3390/cancers17071226 · Cited by 2 · see citing works

Road Map to Defeat Pancreatic Cancer

Ferguson, L. P., & Tuveson, D. A. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060624-044323 · Cited by 2 · see citing works

Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance

Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2 · see citing works

Identification of cytotoxic constituents from Siegesbeckiae Herba and network pharmacology prediction of their anti-pancreatic cancer mechanisms

Zhang, K., Zhao, Y.-Y., Duan, X.-W., Xu, Y., Yao, Y., You, C., Cui, Y., & Jiang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-18358-3 · Cited by 1 · see citing works

Proteomics- and BRET- screens identify SPRY2 as a Ras effector that impacts its membrane organization

Pavic, K., Hood, F. E., Duval, C. J., Manoharan, G. B., Laurini, C., Siddiqui, F. A., Mo, S., Prior, I. A., & Abankwa, D. (2025) · iScience · doi:10.1016/j.isci.2025.113974 · Cited by 1 · see citing works

A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior

Fatima, M., Haider, N., Cain, S. A., Acharya, B. R., Chastney, M. R., Zha, J., Jones, M., Warwood, S., Knight, D., O'Reilly, D. A., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113421 · Cited by 1 · see citing works

KRAS combination strategies: How well aligned is clinical and preclinical research?

Nadal, E., Ambrogio, C., Santamarı́a, D., & Lindsay, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00018-8 · Cited by 1 · see citing works

Impact of Mutational Status on Intracellular Effects of Cell‐Permeable CaaX Peptides in Pancreatic Cancer Cells

Klußmann, M., Matijass, M., & Neundorf, I. (2025) · ChemBioChem · doi:10.1002/cbic.202401076

Remodeling of KRAS interactome induced by clinically relevant RAS inhibitors reveals convergent responses and a KRAS-mediated regulation of directional cell migrationPreprint

Yang, Y., Cho, C. Y., Brock, A., Quackenbush, D., Chen, K., Lo, F., Benes, C. H., & Haling, J. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.14.688534

Unlocking drug sensitivity in KRAS

MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279

RAS and KRAS Inhibitors in Cancer Therapeutic Mechanisms and Resistance: Scoping Review with ☸SAIMSARA

SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsaradc4d1e0f

Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses

Yang, Y., Liu, T., Cho, C. Y., Liu, X., Brock, A., Quackenbush, D., Chen, K., Lo, F., Benes, C. H., & Haling, J. R. (2026) · Oncogene · doi:10.1038/s41388-026-04017-y

Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancerPreprint

Cheng, D. K., Oni, T. E., Park, Y., Thalappillil, J. S., Ting, H.-C., Alagesan, B., Prasad, N. V., Rivera, K. D., Pappin, D., Aelst, L. V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.14.295394 · Cited by 3 · see citing works

Abstract B056: Wild-type RAS/MAPK signaling complexes mediate adaptive resistance to KRAS inhibition in PDAC

Ge, X., Ruiz, C. F., Li, W., Quiñones-Avilés, Y., & Muzumdar, M. D. (2022) · Cancer Research · doi:10.1158/1538-7445.panca22-b056

PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition

Ge, X., Singh, J., Li, W., Bishop, C. S., Ruiz, C. F., Stites, E. C., Bhattacharyya, M., Liu, Y., & Muzumdar, M. D. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3625 · Cited by 4 · see citing works

Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis

Khan, I., MarElia, C. B., Lefler, J. E., Zuberi, M., Denbaum, E., Koide, A., Connor, D. M., Broome, A., Pécot, T., Timmers, C. D., et al. (2021) · Small GTPases · doi:10.1080/21541248.2021.1906621 · Cited by 14 · see citing works

Abstract B078: A complex of NF1 and SPRED2 non-canonically behave as tumor promoters in pancreatic cancer

Kim, S. Y., Ting, H.-C., Deschênes, A., Kastan, J. P., Park, Y., & Tuveson, D. A. (2024) · Cancer Research · doi:10.1158/1538-7445.panca2023-b078